Mohamed Adel Bakr

Mohamed Adel Bakr

Auto-generated profile, based on publicly available information

Mohamed Adel Bakr

Urology and Nephrology Center, Mansoura University, Mansoura, Egypt

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2003 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
AEAmgad E. El-Agroudy
Amgad E. El-Agroudy
NHNabil A. Hassan
Nabil A. Hassan
MBMohamed A. Bakr
Mohamed A. Bakr
MFMohamed A. Foda
Mohamed A. Foda
ASAhmed Shokeir
Ahmed Shokeir
MGMohamed A. Ghoneim
Mohamed A. Ghoneim
Background/Aims: There have been conflicting reports showing that kidneys from small donors may be at risk for graft loss if they are transplanted into large recipients. The aim of this work was to examine the donor/recipient body weight ratio (D/RBWR) on patient and graft outcome. Methods: During the period from January 1990 to January 2002, 856 kidney transplants were performed. Of these, 776 kidney transplant recipients were selected after exclusion of pediatric, second transplant patients and those with a body mass index of ≧35. All patients achieved a minimum follow-up of 1-year. According to D/RBWR, patients were divided into 3 groups: low (≤0.9), medium (0.91–1.2) and high (≧1.2). Data were collected on graft function, acute and chronic rejection, post-transplant complications, and 1- and 5-year graft and patient survival. Results: There was a statistically significant increase in the incidence of chronic rejection, post-transplant hypertension and diabetes mellitus in the low group. The incidence and frequency of acute rejection episodes were nearly the same in the 3 groups. Graft function, estimated by serum creatinine at 1 year, was significantly lower in the low group. The 5-year graft and patient survival was 71, 80, 88 and 81, 85 and 92%, in the low, medium and high groups, respectively. Conclusions: We conclude that a low D/RBWR may contribute to inferior long-term renal allograft survival. The hyperfiltration hypothesis due to low nephron mass in the low D/RBWR group may explain these findings.

1 May 2005 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
AHAhmed F. Hamdy
Ahmed F. Hamdy
AEAmgad E. El‐Agroudy
Amgad E. El‐Agroudy
MBMohamed A. Bakr
Mohamed A. Bakr
AMAmani Mostafa
Amani Mostafa
MEMahmoud El‐Baz
Mahmoud El‐Baz
MGMohamed A. Ghoneim
Mohamed A. Ghoneim
Between May 2001 and January 2003, 132 live donor renal allotransplant recipients were included in a prospective, randomized controlled trial where they were divided into two groups. All patients received steroids and basiliximab induction therapy. For maintenance immunosuppression, tacrolimus and sirolimus were used in group A. In group B, mycophenolate mofetil (MMF) and sirolimus were utilized. Patients were followed up for a minimum of 24 months. One-year patient and graft survival rates were not significantly different between group A (96.9%, 92.3%) and group B (100%, 98.4%), respectively. However, the incidence of biopsy-proven acute rejection was less in group B but the difference was not statistically significant (13.5% vs. 18.5% in group A). Statistically significant better renal function was encountered among group B patients at two years post-transplantation as measured by serum creatinine (1.25 vs. 1.43 mg/dl; P = 0.017) and calculated glomerular filtration rate (GFR) (94.9 vs. 79.6 ml/min; P = 0.005). One year protocol biopsies showed insignificant differences relative to chronic allograft damage index (CADI) between either group (Group A: 2.41 vs. Group B: 2.69; P = 0.436). Similar outcome was noted among patients in whom calcineurin inhibitors were not included in their immunosuppressive regimen. The long term impact of this observation on graft survival and function needs longer follow up.

1 January 2010 in International Journal of Nephrology
Verified
Journal Article
Open access
PDF file
MFMohamed Ashraf Fouda
Mohamed Ashraf Fouda
OGosama Gheith
osama Gheith
ARAyman Refaie
Ayman Refaie
MEMohamed El-Saeed
Mohamed El-Saeed
ABAdel Bakr
Adel Bakr
MSMohamed Sobh
Mohamed Sobh
Kimura disease (KD) is a chronic inflammatory disorder with angiolymphatic proliferation, usually affecting young men of Asian race but is rare in other races. The etiology of KD is still unknown. It is often accompanied by nephrotic syndrome. Herein, we present an atypical manifestation of Kimura disease occurring in a Caucasian man with steroid-responsive early membranous glomerulonephritis. Kimura disease can present atypically in a middle-aged Caucasian man with secondary steroid-responsive nephrotic syndrome. Steroid, endoxan, and MMF can be used safely and successfully in such situation. The diagnosis of KD can be difficult and misleading, and patients with this disease are often evaluated using avoidable procedures by just not being aware of KD.

24 June 2005 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
MEMohamed A. El-Far
Mohamed A. El-Far
MBMohamed A. Bakr
Mohamed A. Bakr
SFSami E. Farahat
Sami E. Farahat
EEElsaid A. Abd El-Fattah
Elsaid A. Abd El-Fattah

1 August 2005 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
MGM.E. Ghanem
M.E. Ghanem
LEL.A. El-Baghdadi
L.A. El-Baghdadi
ABA.M. Badawy
A.M. Badawy
MBM.A. Bakr
M.A. Bakr
MSM.A. Sobhe
M.A. Sobhe
MGM.A. Ghoneim
M.A. Ghoneim

1 June 2008 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
AHAhmed F. Hamdy
Ahmed F. Hamdy
MBMohamed A. Bakr
Mohamed A. Bakr
MGMohamed A. Ghoneim
Mohamed A. Ghoneim
Calcineurin inhibitor (CNI) nephrotoxicity is a major concern after renal transplantation. To investigate the safety and efficacy of a CNI-free immunosuppressive regimen, 132 live-donor renal transplant recipients were included in a prospective, randomized controlled trial. All patients received induction therapy with basiliximab and steroids. The patients were randomized to a maintenance immunosuppression regimen that included steroids, sirolimus, and either low-dose tacrolimus or mycophenolate mofetil (MMF). Over a mean follow-up period of approximately 5 yr, patient and graft survival did not significantly differ between the two maintenance regimens. Patient survival was 93.8% and 98.5% in the tacrolimus/sirolimus and MMF/sirolimus groups, respectively, and graft survival was 83% and 88%, respectively. However, the MMF/sirolimus group had significantly better renal function, calculated by Cockcroft-Gault, from the second year post-transplant until the last follow-up. In addition, this group was less likely to require a change in their primary immunosuppression regimen than the tacrolimus/sirolimus group (20.8% versus 53.8%, P = 0.001). The safety profile was similar between groups. In summary, after long-term follow-up, a CNI-free maintenance regimen consisting of sirolimus, MMF, and steroids was both safe and efficacious among low to moderate immunologic risk renal transplant recipients.